WordNet

a substance that exerts some force or effect
a businessman who buys or sells for another in exchange for a commission (同)factor, broker
any agent or representative of a federal agency or bureau (同)federal agent
a representative who acts on behalf of other persons or organizations
an active and efficient cause; capable of producing a certain effect; "their research uncovered new disease agents"

PrepTutorEJDIC

『代理人』;周旋人 / 働き(作用)を起こすもの;作用物,薬剤 / (政府機関,特にFBI,CIAなどの)部員,機関員

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 起立性低血圧および食後低血圧の治療 treatment of orthostatic and postprandial hypotension
2. 喘息または再発性喘鳴を有する小児に対する麻酔 anesthesia for the child with asthma or recurrent wheezing
3. 外科手術で使用される局所止血剤および生体組織接着剤の概要 overview of topical hemostatic agents and tissues adhesives used in surgery
4. 眼の待機手術に対する麻酔 anesthesia for elective eye surgery
5. Role of mucoactive agents and secretion clearance techniques in COPD

English Journal

1,4-Dihydropyridines: A Class of Pharmacologically Important Molecules.

Khedkar SA, Auti PB.Author information Department of Pharmaceutical Chemistry, STES's Sinhgad Institute of Pharmacy, Narhe, Pune-41. Maharashtra. India. pratibhaauti@yahoo.com.AbstractThe 1,4-dihydropyridines (DHPs), a class of drugs possess a wide variety of biological and pharmacological actions, have represented one of the most important groups of calcium-channel modulating agents and have experienced widespread use in the treatment of cardiovascular disease which include antihypertensive, antianginal, vasodilator and cardiac depressants activities. It also shows antibacterial, anticancer, antileishmanial, anticoagulant, anticonvulsant, antitubercular, antioxidant, antiulcer, CFTR, antimalarials, neuroprotection properties, HIV-1 protease inhibitors, antifertility activities and many more. There are many marketed drugs which contain 1,4-dihydropyridines ring as basic scaffold. In this review, attempts have been made to disclose various therapeutic applications of 1,4-dihydropyridine derivatives which have been reported during the period of 2001-2011.
Mini reviews in medicinal chemistry.Mini Rev Med Chem.2013 Nov 19. [Epub ahead of print]
The 1,4-dihydropyridines (DHPs), a class of drugs possess a wide variety of biological and pharmacological actions, have represented one of the most important groups of calcium-channel modulating agents and have experienced widespread use in the treatment of cardiovascular disease which include anti
PMID 24251802

Ranolazine for congenital and acquired late INa-linked arrhythmias: in silico pharmacological screening.

Moreno JD, Yang PC, Bankston JR, Grandi E, Bers DM, Kass RS, Clancy CE.Author information From the Tri-Institutional MD-PhD Program, Weill Cornell Medical College/The Rockefeller University/Sloan-Kettering Cancer Institute, New York, NY.AbstractRATIONALE: The antianginal ranolazine blocks the human ether-a-go-go-related gene-based current IKr at therapeutic concentrations and causes QT interval prolongation. Thus, ranolazine is contraindicated for patients with preexisting long-QT and those with repolarization abnormalities. However, with its preferential targeting of late INa (INaL), patients with disease resulting from increased INaL from inherited defects (eg, long-QT syndrome type 3 or disease-induced electric remodeling (eg, ischemic heart failure) might be exactly the ones to benefit most from the presumed antiarrhythmic properties of ranolazine.
Circulation research.Circ Res.2013 Sep 13;113(7):e50-61. doi: 10.1161/CIRCRESAHA.113.301971. Epub 2013 Jul 29.
RATIONALE: The antianginal ranolazine blocks the human ether-a-go-go-related gene-based current IKr at therapeutic concentrations and causes QT interval prolongation. Thus, ranolazine is contraindicated for patients with preexisting long-QT and those with repolarization abnormalities. However, with
PMID 23897695

Pharmacology at work for cardio-oncology: ranolazine to treat early cardiotoxicity induced by antitumor drugs.

Minotti G.Author information CIR and Drug Sciences, University Campus Bio-Medico, Rome, Italy. g.minotti@unicampus.itAbstractAntitumor drugs may cause asymptomatic diastolic dysfunction that introduces a lifetime risk of heart failure or myocardial infarction. Cardio-oncology is the discipline committed to the cardiac surveillance and management of cancer patients and survivors; however, cardio-oncology teams do not always attempt to treat early diastolic dysfunction. Common cardiovascular drugs, such as β blockers or angiotensin-converting enzyme inhibitors or others, would be of uncertain efficacy in diastolic dysfunction. This perspective describes the potential value of ranolazine, an antianginal drug that improves myocardial perfusion by relieving diastolic wall tension and dysfunction. Ranolazine acts by inhibiting the late inward sodium current, and pharmacological reasonings anticipate that antitumor anthracyclines and nonanthracycline chemotherapeutics might well induce anomalous activation of this current. These notions formed the rationale for a clinical study of the efficacy and safety of ranolazine in cancer patients. This study was not designed to demonstrate that ranolazine reduced the lifetime risk of cardiac events; it was designed as a short term proof-of-concept study that probed the following hypotheses: 1) asymptomatic diastolic dysfunction could be detected a few days after patients completed antitumor therapy, and 2) ranolazine was active and safe in relieving echocardiographic and/or biohumoral indices of diastolic dysfunction, measured at 5 weeks or 6 months of ranolazine administration. These facts illustrate the translational value of pharmacology, which goes from identifying therapeutic opportunities to validating hypotheses in clinical settings. Pharmacology is a key to the success of cardio-oncology.
The Journal of pharmacology and experimental therapeutics.J Pharmacol Exp Ther.2013 Sep;346(3):343-9. doi: 10.1124/jpet.113.204057. Epub 2013 Jul 1.
Antitumor drugs may cause asymptomatic diastolic dysfunction that introduces a lifetime risk of heart failure or myocardial infarction. Cardio-oncology is the discipline committed to the cardiac surveillance and management of cancer patients and survivors; however, cardio-oncology teams do not alway
PMID 23818683

Japanese Journal

Clinically applicable antianginal agents suppress osteoblastic transformation of myogenic cells and heterotopic ossifications in mice

Journal of bone and mineral metabolism 31(1), 26-33, 2013-01-30
NAID 10031168834

第12回体表心臓微小電位研究会 TWA voltage,自律神経機能および血漿カテコラミンに及ぼす各種抗狭心症薬の比較検討

心臓 35(Supplement1), 8-10, 2003
NAID 130004136385

Evaluation of Antianginal Agents by Autonomic Nerve Functions, Microvolt T wave-Alternans and Plasma Catecholamine Levels in Patients with Post-Myocardial Infarction

Circulation journal : official journal of the Japanese Circulation Society 66(Supplement_I), 658, 2002-03-31
NAID 110002637220